The P-Shot for Erectile Dysfunction in India: A Clinical Patient Guide | ALIV

Erectile dysfunction (ED) affects an estimated 30–40% of Indian men over 40 — and remains, despite its prevalence, one of the least openly discussed health concerns in clinical settings. Many men managing ED have tried pharmaceutical management (PDE5 inhibitors — sildenafil, tadalafil) with varying results and seek alternatives that address the underlying tissue biology rather than providing temporary pharmacological support. The P-Shot (Priapus Shot) — an autologous PRP injection into penile tissue — offers a biologically grounded approach to ED that works through mechanisms entirely different from pharmaceutical management, and that is particularly relevant for patients in whom pharmaceutical ED management has been inadequate or poorly tolerated.

The Mechanism: Growth Factors and Penile Tissue Health

Erectile function depends on a complex interplay of vascular, neurological, and smooth muscle factors — primarily the ability of penile arteries to dilate rapidly (increasing blood flow), the corpus cavernosum smooth muscle to relax and accommodate blood under pressure, and the veno-occlusive mechanism to trap blood and maintain erection. ED typically reflects failure at one or more of these levels — most commonly vascular dysfunction driven by endothelial damage from metabolic factors (hypertension, diabetes, dyslipidaemia, smoking), age-related attrition of penile smooth muscle, or neurogenic impairment from prostate surgery or diabetic neuropathy.

The P-Shot delivers concentrated PRP growth factors — PDGF, VEGF, IGF-1, and TGF-β — directly into the corpus cavernosum and around the glans. These growth factors support: angiogenesis (VEGF stimulates new capillary formation in the penile vascular bed — addressing the endothelial dysfunction of vascular ED); smooth muscle regeneration (TGF-β and IGF-1 support corpus cavernosum smooth muscle cell health — the smooth muscle that must relax adequately for erection); neuroregeneration (NGF and BDNF — present in some PRP preparations — support penile sensory nerve health, relevant for neuropathic and post-surgical ED); and reduced fibrosis (anti-fibrotic growth factor signals oppose the penile fibrosis that accumulates with age and ED duration — fibrosis reduces the compliance of the corpus cavernosum and impairs erection quality). The mechanism is direct and biologically coherent — this is not an unsubstantiated wellness claim. See: ALIV specialty therapy pillar.

Who Is an Appropriate P-Shot Candidate

The patient profile with the best clinical rationale for P-Shot: ED with a vascular component (organic ED driven by endothelial dysfunction — the most common type in India's urban male population with metabolic comorbidities); ED that is inadequately controlled on PDE5 inhibitors or where PDE5 inhibitors produce unacceptable side effects; post-prostatectomy ED (neurogenic and vascular component together); ED associated with Peyronie's disease (where intracorporal PRP may support the anti-fibrotic remodelling of the penile plaque); and ED in the context of diabetes or hypertension where the vascular driver is primary. Psychogenic ED (pure psychological cause without vascular or neurogenic component) is less likely to respond to a biological intervention targeting tissue health.

Honest Expectations

The P-Shot is not a guaranteed cure for ED and should not be positioned as such. Clinical evidence for the P-Shot specifically — as opposed to the PRP mechanism components that have broader evidence — is at an early stage: small studies, mixed methodology, and limited placebo-controlled data. ALIV's clinical position is that the mechanistic rationale is strong, the safety profile is excellent (autologous PRP, same-day preparation, well-tolerated administration under local anaesthesia), and the early clinical evidence is positive but not yet conclusive. Patients with realistic expectations of meaningful improvement in erectile function quality — rather than instantaneous restoration of youthful function — are the most appropriate candidates. Response typically develops over four to twelve weeks post-procedure.

Is the P-Shot painful?

The procedure is performed under topical and local anaesthetic — a penile nerve block using local anaesthetic administered by the physician before the PRP injection. Most patients report pressure and mild discomfort during the injection under this anaesthesia, not sharp pain. The procedure takes approximately thirty minutes from start to finish. There is no significant recovery period — patients can return to normal activities the same day; sexual activity is typically abstained from for forty-eight hours after the procedure to allow the growth factor signalling to establish without additional vascular stress at the injection site.

Can the P-Shot be combined with PDE5 inhibitors?

Yes — and this is clinically rational. PDE5 inhibitors (sildenafil, tadalafil) work through the nitric oxide-cGMP pathway to pharmacologically relax smooth muscle; the P-Shot works through growth factor-driven tissue regeneration to improve the inherent capacity of the penile tissue to respond to arousal signals. The two mechanisms are complementary rather than competing. Many patients find that the P-Shot improves their response to PDE5 inhibitors — or reduces the dose required for adequate effect — rather than replacing them entirely in the short term. Over three to six months of tissue regeneration, some patients find improved spontaneous function that reduces pharmaceutical dependency.

How long do P-Shot results last?

Early clinical data suggests meaningful improvement lasting six to eighteen months from a single procedure in responsive patients. Repeat procedures at twelve to eighteen month intervals are the typical maintenance approach for patients with chronic ED who have responded well to the initial P-Shot. The duration of benefit reflects the biological reality of the procedure: the growth factor-driven tissue regeneration produces sustained improvement in the vascular and smooth muscle biology — but the underlying conditions driving ED (metabolic syndrome, age, diabetes) continue, and periodic renewal of the regenerative signal maintains the benefit.